MaxiVax: MaxiVAX raises additional CHF5 million
MaxiVAX SA, developing novel anti-cancer vaccines, a Series B 2 round of CHF 5 million from new and existing investors. In addition, the company had been awarded a Horizon 2020 EIC Accelerator grant.
Read full article »
MaxiVAX develops the first active immunotherapy based on encapsulated cells for treating cancers.
Read more